Pat Sharp
@patsharp.bsky.social
Drug developer | Co-founder of Gate Bio | Fmr Big Pharma | Inventing small molecule medicines | Artist | Polymath
Great year for rare disease drugs
November 28, 2025 at 9:27 AM
Great year for rare disease drugs
If it’s PROTAC linkerology sure, you can be relatively confident of the mechanism, but if it’s a glue or HTS library it’s tougher.
November 28, 2025 at 6:28 AM
If it’s PROTAC linkerology sure, you can be relatively confident of the mechanism, but if it’s a glue or HTS library it’s tougher.
I think D2B is particularly challenging for degrader read-outs. The problem is that there are many mechanisms that can lead to reduced protein level, both direct and indirect. Careful controls and validations experiments need to be run which can compromise the efficiency gains of D2B.
November 28, 2025 at 6:25 AM
I think D2B is particularly challenging for degrader read-outs. The problem is that there are many mechanisms that can lead to reduced protein level, both direct and indirect. Careful controls and validations experiments need to be run which can compromise the efficiency gains of D2B.
Lots of really good references go a long way. You’re not usually hiring most people to give presentations. If the science is good but the presentation is bad (nervous speaking, poor slide formatting etc.) but everyone says they worked with says they are a rockstar then they’re probably amazing!
June 5, 2025 at 10:34 AM
Lots of really good references go a long way. You’re not usually hiring most people to give presentations. If the science is good but the presentation is bad (nervous speaking, poor slide formatting etc.) but everyone says they worked with says they are a rockstar then they’re probably amazing!
Just got around to trying. Was excellent for single compounds but failed on batches of 2 or more.
April 28, 2025 at 4:49 AM
Just got around to trying. Was excellent for single compounds but failed on batches of 2 or more.